| 21 | 0 | 110 |
| 下载次数 | 被引频次 | 阅读次数 |
肝癌作为全球第六大常见诊断癌症及第三大癌症死亡原因，严重威胁患者生命健康。溶瘤病毒疗法作为一种新型免疫治疗手段，凭借其高选择性复制及诱导细胞病变效应的特性，为肝癌治疗带来新的希望。免疫检查点抑制剂则通过解除肿瘤细胞对免疫系统的抑制，激活机体抗肿瘤免疫应答发挥作用。两者联合应用时展现出显著的协同效应，在逆转肿瘤免疫抑制微环境、增强抗肿瘤疗效方面优势突出。本文将围绕溶瘤病毒与免疫检查点抑制剂的协同作用机制及临床应用进展进行综述，旨在为肝癌治疗提供新的思路与参考，助力拓展更有效的治疗策略以惠及更多患者。
Abstract：Hepatocellular carcinoma(HCC) is the sixth most commonly diagnosed malignancy worldwide and the third leading cause of cancer-related mortality, posing a major global health burden. Oncolytic virotherapy has emerged as a promising immunotherapeutic approach for HCC, owing to its ability to selectively replicate within tumor cells and induce cytopathic effects. Immune checkpoint inhibitors(ICIs), in contrast, restore antitumor immunity by relieving tumor-induced immune suppression and reactivating host immune responses. When used in combination, these two modalities demonstrate pronounced synergistic effects, particularly in reversing the immunosuppressive tumor microenvironment and enhancing therapeutic efficacy. This review summarizes current knowledge on the mechanisms underlying the synergy between oncolytic viruses and ICIs, as well as recent advances in their clinical application. It aims to provide a scientific basis for optimizing combination strategies and to inform the development of more effective therapeutic approaches for HCC.
[1]Rumgay H, Ferlay J, de Martel C, et al. Global,regional and national burden of primary liver cancer by subtype[J]. Eur J Cancer, 2022, 161:108-118. DOI:10. 1016/j. ejca. 2021. 11. 023.
[2]Cai Y, Wang W, Jiao Q, et al. Nanotechnology for the diagnosis and treatment of liver cancer[J]. Int J Nanomedicine, 2024, 19:13805-13821. DOI:10. 2147/IJN. S490661.
[3]Shi JF, Cao M, Wang Y, et al. Is it possible to halve the incidence of liver cancer in China by 2050?[J]. Int J Cancer, 2021, 148(5):1051-1065. DOI:10. 1002/ijc. 33313.
[4]Wang Z, Wang Y, Gao P, et al. Immune checkpoint inhibitor resistance in hepatocellular carcinoma[J].Cancer Lett, 2023, 555:216038. DOI:10. 1016/j.canlet. 2022. 216038.
[5]Rezaee-Zavareh MS, Yeo YH, Wang T, et al. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC:a systematic review and individual patient data meta-analysis[J]. J Hepatol,2025, 82(1):107-119. DOI:10. 1016/j.jhep. 2024. 06. 042.
[6]蓝林晨，刘晓辉，卢姣汐，等.上市呼吸道合胞病毒疫苗临床研究进展[J].病毒学报，2025, 41(3):915-922. DOI:10. 13242/j. cnki. bingduxuebao. 240327.
[7]Muthukutty P, Yoo SY. Oncolytic Virus Engineering and Utilizations:Cancer Immunotherapy Perspective[J]. Viruses,2023,15(8):1645. DOI:10. 3390/v15081645.
[8]Ma R, Li Z, Chiocca EA, et al. The emerging field of oncolytic virus-based cancer immunotherapy[J]. Trends Cancer, 2023, 9(2):122-139. DOI:10. 1016/j.trecan. 2022. 10. 003.
[9]Ye Y, Liu Y. Oncolytic virus therapy in hepatocellular carcinoma[J]. Oncol Res, 2025, 33(7):1593-1610.DOI:10. 32604/or. 2025. 061857.
[10]Huang Z, Guo H, Lin L, et al. Application of oncolytic virus in tumor therapy[J]. J Med Virol, 2023, 95(4):e28729. DOI:10. 1002/jmv. 28729.
[11]刘夏飞，段招军.基于质粒的轮状病毒反向遗传学研究进展[J].病毒学报，2023, 39(2):549-560. DOI:10. 13242/j. cnki. bingduxuebao. 004276.
[12]Hu M, Liao X, Tao Y, et al. Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma[J]. Front Immunol, 2023,14:1285113. DOI:10. 3389/fimmu. 2023. 1285113.
[13]Hecht JR, Oberoi A, Garralda Cabanas E, et al. Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma[J].Oncologist, 2025, 30(3):oyae203. DOI:10. 1093/oncolo/oyae203.
[14]Jing C, Zhu T, Zhang Y, et al. The combination treatment of oncolytic adenovirus H101 with transcatheter arterial embolization sequential thermal ablation for hepatocellular carcinoma:a retrospective study[J]. Front Oncol, 2025, 15:1623877. DOI:10. 3389/fonc. 2025. 1623877.
[15]李鹏尉，沈宇清.免疫检查点分子在慢性HBV感染中对T细胞功能影响的研究进展[J].病毒学报，2021,37(2):465-470. DOI:10. 13242/j. cnki.bingduxuebao. 003914.
[16]Hossain MA. A comprehensive review of immune checkpoint inhibitors for cancer treatment[J]. Int Immunopharmacol, 2024, 143:113365. DOI:10. 1016/j. intimp. 2024. 113365.
[17]Hossen MM, Ma Y, Yin Z, et al. Current understanding of CTLA-4:from mechanism to autoimmune diseases[J]. Front Immunol, 2023, 14:1198365. DOI:10. 3389/fimmu. 2023. 1198365.
[18]Kong X, Zhang J, Chen S, et al. Immune checkpoint inhibitors:breakthroughs in cancer treatment[J].Cancer Biol Med, 2024:1-11. DOI:10. 20892/j.issn. 2095-3941. 2024. 0055.
[19]Tang C, Welsh JW, de Groot P, et al. Ipilimumab with stereotactic ablative radiation therapy:phase I results and immunologic correlates from peripheral T cells[J]. Clin Cancer Res, 2017, 23(6):1388-1396.DOI:10. 1158/1078-0432. ccr-16-1432.
[20]Wang Z, You P, Yang Z, et al. PD-1/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer:a meta-analysis on their efficacy and safety[J].BMC Cancer, 2024, 24(1):1339. DOI:10. 1186/s12885-024-13105-9.
[21]Melero I, de Miguel Luken M, de Velasco G, et al.Neutralizing GDF-15 can overcome anti-PD-1 and antiPD-L1 resistance in solid tumours[J]. Nature, 2025,637(8048):1218-1227. DOI:10. 1038/s41586-024-08305-z.
[22]Tang Q, Zhao S, Zhou N, et al. PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors(Review)[J]. Int J Oncol, 2023, 62(4):49.DOI:10. 3892/ijo. 2023. 5497.
[23]Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma:a multicentre, open-label, parallel-group,randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4):571-580. DOI:10. 1016/S1470-2045(20)30011-5.
[24]Lee DW, Cho EJ, Lee JH, et al. Phase II study of avelumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib[J]. Clin Cancer Res, 2021, 27(3):713-718. DOI:10. 1158/1078-0432. ccr-20-3094.
[25]Pan B, Zhang X, Ye D, et al. Intratumoral Brevibacillus parabrevis enhances antitumor immunity by inhibiting NK cell ferroptosis in hepatocellular carcinoma[J]. Cell Death Dis, 2025, 16(1):407.DOI:10. 1038/s41419-025-07733-7.
[26]Moreno R. Mesenchymal stem cells and oncolytic viruses:joining forces against cancer[J]. J Immunother Cancer, 2021, 9(2):e001684. DOI:10. 1136/jitc-2020-001684.
[27]Wu R, Tong S, Yin J, et al. Oncolytic vaccinia virus acts synergistically with anti-PD-L1 antibody to enhance the killing of colon cancer cells by CD8+T cells[J].Pathol Res Pract, 2023, 247:154535. DOI:10. 1016/j.prp. 2023. 154535.
[28]Feng Y, Yang H, Liang G, et al. Immune checkpoint inhibitors combined with oncolytic virotherapy:synergy,heterogeneity, and safety in cancer treatment[J]. Oncol Res, 2025, 33(12):3801-3836. DOI:10. 32604/or. 2025. 067824.
[29]Shen Y, Bai X, Zhang Q, et al. Oncolytic virus VG161in refractory hepatocellular carcinoma[J]. Nature,2025, 641(8062):503-511. DOI:10. 1038/s41586-025-08717-5.
[30]Lei G, Li B, Yang H, et al. Therapeutic efficacy of an oncolytic influenza virus carrying an antibody against programmed cell death 1 in hepatocellular carcinoma[J].Hum Gene Ther, 2022, 33(5-6):309-317. DOI:10. 1089/hum. 2021. 167.
[31]Xie C, Zheng X, He S, et al. Clinical evaluation of M1-c6v1 oncolytic virus combined with camrelizumab and apatinib in advanced hepatocellular carcinoma[J]. Clin Cancer Res, 2025, 31(20):4288-4298. DOI:10. 1158/1078-0432. ccr-25-1620.
[32]Yi L, Ning Z, Xu L, et al. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma:an openlabel, single-arm, pilot study[J]. ESMO Open, 2024,9(2):102239. DOI:10. 1016/j. esmoop. 2024. 102239.
[33]Chesney JA, Puzanov I, Collichio FA, et al.Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma:5-year final analysis of a multicenter,randomized, open-label, phase II trial[J]. J Immunother Cancer, 2023, 11(5):e006270. DOI:10. 1136/jitc-2022-006270.
[34]Nassiri F, Patil V, Yefet LS, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma:a phase 1/2 trial[J]. Nat Med, 2023, 29(6):1370-1378. DOI:10. 1038/s41591-023-02347-y.
[35]Zhu S, Zhong Q, Zhang Y, et al. Phase I clinical trial of a recombinant oncolytic virus injection combined with PD-1 antibody-based gene therapy for recurrent head and neck cancer in China:an open-label study[J]. Virus Res, 2025, 361:199639. DOI:10. 1016/j.virusres. 2025. 199639.
[36]Dummer R, Robert C, Scolyer RA, et al. Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma:a phase 1/2 trial[J]. Nat Med, 2025, 31(1):144-151.DOI:10. 1038/s41591-024-03411-x.
基本信息:
中图分类号:R735.7
引用信息:
[1]张宝午,王东东,沈锋.溶瘤病毒联合免疫检查点抑制剂在肝癌中的协同及临床应用进展[J].病毒学报().
基金信息:
河南省医学科技攻关计划联合共建项目（项目号：LHGJ20210708）,题目：多模态磁共振成像联合影像组学评估肝癌TACE术后效果研究
2026-06-08
2026-06-08
2026-06-08